Work

Case Report: Serum AKR1B10 as a complementary marker for the detection of AFP-negative hepatocellular carcinoma – a report of two cases

Year: 2026

Type: article

Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with chronic hepatitis B and C viral infections being major risk factors. To date, the lack of effective methods for monitoring the progression from viral infection to cancer remains a clinical issue. Alpha-fetoprotein (AFP) is a serum marker used for the detection of HCC; however, AFP levels remain negative in 30-40% of HCC cases and 60-70% of early-stage HCC cases. Aldo-keto reductase 1B10 (AKR1B10) has been reported as a serum marker for HCC. In this study, we report two cases of hepatitis B-related HCC that were persistently AFP-negative but showed a marked increase in serum AKR1B10 levels. These cases illustrate the complementary role of serum AKR1B10 in the diagnosis of AFP-negative HCC, serving as a hypothesis-generating approach. A prospective large-scale study is warranted to define the clinical value of AKR1B10 in AFP-negative HCC.

Source: Frontiers in Medicine

DOI: 10.3389/fmed.2026.1756950

Authors: Ye Gao, Lihua Xie, Yuting Ou, Xi Zeng, Deliang Cao, Jianping Yin

Institutions: University of South China, First Affiliated Hospital of University of South China

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801